Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Shah, Maunank ^a   Chihota, Violet ^b   Coetzee, Gerrit ^c   Churchyard, Gavin ^b,d,e   Dorman, Susan E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AURUM INSTITUTE   (South Africa)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Costs; Diagnostics; Laboratory; Tuberculosis

Indexed keywords

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DRUG RESISTANT TUBERCULOSIS; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; MOLECULAR DIAGNOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SOUTH AFRICA; SPUTUM CYTODIAGNOSIS;

EID: 84880933759     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-352     Document Type: Article

References (15)

1. WHO Multidrug and Extensively drug-resistant TB: 2010 Global Report on Surveillance and Response 2010, http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf, WHO.
2. Molecular Line Probe Assays for Rapid Screening of Patients at Risk of Multidrug-Resistant Tuberculosis. [http://www.who.int/tb/features_archive/policy_statement.pdf].
3. Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Drug Resistant Tuberculosis: Policy Statement. [http://whqlibdoc.who.int/publications/2011/9789241501545_eng.pdf].
4. Shah NS, Lan NT, Huyen MN, Laserson K, Iademarco MF, Binkin N, Wells C, Varma JK. Validation of the line-probe assay for rapid detection of rifampicin-resistant Mycobacterium tuberculosis in Vietnam. Int J Tuberc Lung Dis 2009, 13(2):247-252.
5. Huyen MN, Tiemersma EW, Lan NT, Cobelens FG, Dung NH, Sy DN, Buu TN, Kremer K, Hang PT, Caws M, et al. Validation of the GenoType MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam. BMC Infect Dis 2010, 10:149. 10.1186/1471-2334-10-149, 2901356, 20525271.
6. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008, 177(7):787-792. 10.1164/rccm.200709-1436OC, 18202343.
7. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010, 363(11):1005-1015. 10.1056/NEJMoa0907847, 2947799, 20825313.
8. Negotiated Prices for Xpert MTB/RIF. [http://www.finddiagnostics.org/about/what_we_do/successes/find-negotiated-prices/xpert_mtb_rif.html].
9. Global TB Programme, World Health Organization. Laboratory services in TB control, Part II: Microscopy. WHO/TB/98.258. [http://whqlibdoc.who.int/hq/1998/WHO_TB_98.258_(part2).pdf].
10. Kent P T KGP Public Health mycobacteriology: a fuide for the level III laboratory 1985, Atlanta, GA, USA: Centers for Disease Control, Kent P T KGP.
11. Negotiated Prices and Country List for Line Probe Assay and associated instrumentation. [http://www.finddiagnostics.org/about/what_we_do/successes/find-negotiated-prices/mtbdrplus.html].
12. FIND-Negotiated Prices for BACTEC and MGIT and Country List. [http://www.finddiagnostics.org/about/what_we_do/successes/find-negotiated-prices/bactec-mgit.html].
13. Pricing to the FIND Target Market of 145 Countries. [http://www.cepheidcares.com/tb/cepheid-vision.html].
14. Management of Drug-Resistant Tuberculosis http://www.tbonline.info/media/uploads/documents/mdr-tb_sa_2010.pdf, Management of Drug-Resistant Tuberculosis.
15. Jacobson KR, Theron D, Kendall EA, Franke MF, Barnard M, van Helden PD, Victor TC, Streicher EM, Murray MB, Warren RM. Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis 2013, 56(4):503-508. 10.1093/cid/cis920, 23090928.